 |
|
|
|
|
'Abuse-Resistant' Form of OxyContin May Be Near
Remoxy won't give abusers the quick high they seek, study suggests
By Amanda Gardner
HealthDay Reporter
|
| | | | Related Healthscout Videos | |
|
THURSDAY, Sept. 11 (HealthDay News) -- Researchers say they've developed an "abuse-resistant" formulation of the widely prescribed opioid pain medication OxyContin.
The U.S. Food and Drug Administration has granted Remoxy priority review, meaning that action could come as soon as early December, said Dr. Nadav Friedman, chief operating officer of Pain Therapeutics Inc., which developed Remoxy.
Text Continues Below
If approval is granted, said Friedman, who is also co-author of two studies being presented this week at the American Academy of Pain Management's annual meeting, the drug could get on the market "very quickly."
Pain Therapeutics Inc., based in San Mateo, Calif., funded both studies.
Abuse of prescription OxyContin is a major public health issue in the United States, particularly among adolescents and young adults. A federal report issued last week found that while cocaine and methamphetamine use among young adults in the United States fell in 2007 compared with 2006, abuse of prescription pain relievers by young adults rose 12 percent, to 4.6 percent.
And Remoxy isn't the only such abuse-resistant form of oxycodone (the generic name for OxyContin) on the pharmaceutical drawing board. According to the Associated Press, Purdue Pharma in May got a cool reception from an advisory panel at the U.S. Food and Drug Administration for its version of an abuse-resistant oxycodone. However, the company said at the time that it would continue to work on the product.
And in late March, Northvale, N.J.-based Elite Pharmaceuticals, Inc., announced that it planned a phase III clinical trial of a drug that combines oxycodone with the anti-addiction drug naltrexone.
As for Remoxy, Dr. Scott Fishman, chief of the division of pain medicine and professor of anesthesiology at the University of California, Davis and president of the American Pain Foundation, called the new study results "a nice step, but it needs to be approved."
Page: 1 | 2 | Next >>
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 9/11/2008
|
|
SOURCES: Nadav Friedman, M.D., Ph.D., chief operating officer, Pain Therapeutics Inc., San Mateo, Calif.; Scott Fishman, M.D., chief, division of pain medicine, and professor, anesthesiology, University of California, Davis, and president, American Pain Foundation; Sept. 9, 2008, presentations, American Academy of Pain Management annual meeting, Nashville, Tenn.
|
